Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + domvanalimab + chemotherapy versus pembrolizumab + chemotherapy in first-line metastatic non-small cell lung cancer
2022-000578-25Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zimberelimab + domvanalimab + chemotherapy with Pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jun 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000578-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000578-25.